Health Economics›Chronic lymphocytic leukemia›Relapsed or refractory randomized data

Relapsed or refractory randomized data

Chronic lymphocytic leukemia · 17 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 11 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Idelalisib and Ofatumumab Variant #01 Partial	—	R 4 252 351	28d	~16.3 mo	—	~6	~R 5 789 346 PFS proxy · indirect	1
Ofatumumab monotherapy Variant #03	—	R 512 332	28d	~8.1 mo	—	~6	~R 3 073 989 PFS proxy · indirect	4
O-FC Variant #02	—	R 426 746	28d	~28.9 mo	—	~5	~R 1 485 170 PFS proxy · indirect	1
Venetoclax and Rituximab Variant #01	—	R 172 068	28d	—	—	~25	~R 2 619 815 PFS proxy · indirect	2
FCR Variant #07	—	R 120 349	30d	~56.4 mo	—	~5	~R 361 047 PFS proxy · indirect	10
Bendamustine and Rituximab (BR) and Ibrutinib Variant #01	—	R 111 351	28d	—	—	~7	~R 618 713 PFS proxy · indirect	2
Idelalisib and Rituximab Variant #02 Partial	—	R 103 619	28d	~12.6 mo	—	~13	~R 207 238 PFS proxy · indirect	2
Ibrutinib monotherapy Variant #01	—	R 81 964	28d	~44.1 mo	—	~2	~R 163 929 PFS proxy · indirect	15
Ibrutinib and Ublituximab Variant #01 Partial	—	R 80 133	84d	—	—	~7	~R 560 930 indirect	—
Acalabrutinib monotherapy Variant #01	—	R 79 217	28d	~38.4 mo	—	~2	~R 158 435 PFS proxy · indirect	4
Zanubrutinib monotherapy Variant #01	—	R 65 750	28d	—	—	~2	~R 131 500 PFS proxy · indirect	4
Bendamustine and Rituximab (BR) and Idelalisib Variant #01 Partial	—	R 57 122	28d	~20.8 mo	—	~7	~R 187 306 PFS proxy · indirect	1
Bendamustine and Rituximab (BR) Variant #01	—	R 33 874	28d	~40.7 mo	—	~7	~R 237 120 PFS proxy · indirect	13
Fludarabine monotherapy Variant #05	—	R 13 754	28d	~16.5 mo	~52.9 mo	~7	~R 96 278 PFS proxy · indirect	3
Bendamustine monotherapy Variant #01	—	R 7 084	—	~18.3 mo	—	~6	~R 42 504 PFS proxy · indirect	1
Rituximab monotherapy Variant #09 Partial	—	—	28d	~53.2 mo	—	~1	—	5
Duvelisib monotherapy Variant #01 Partial	—	—	28d	~13.3 mo	—	~2	—	1

17 of 17 regimens shown